- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
**Consolidated Financial Summary:**
Dr. Reddy's Laboratories reported consolidated revenue of ₹2800 crore for FY24, reflecting a year-over-year growth of 22% from ₹2467 crore in FY23. This growth was driven by a robust 27.7% increase in the US business, attributed to new product launches, particularly the generic Revlimid, alongside increased base business volumes and favorable currency movements.
EBITDA for the year stood at ₹793 crore with an impressive margin of 28.3%, a significant improvement from 26% in the previous year. This margin enhancement was primarily due to better product mix and moderated pricing pressures. The net profit figures for the year demonstrated a strong operational performance, positioning the EPS favorably as profitability improved due to effective cost management strategies.
Operational costs reflected an increase in R&D spending to 8.2% of revenue, indicating the company’s commitment to innovation, particularly in developing biosimilars. Despite higher capex of ₹2740 crore aimed at sustaining growth, the company maintained a focus on cost efficiency, supported by a gross margin improvement to 70.7%.
On the balance sheet, Dr. Reddy's held a strong cash position of ₹6130 crore and generated positive free cash flow of ₹1090 crore, maintaining a conservative net debt of ₹2000 crore, which results in a net debt/EBITDA ratio of 0.1x, showcasing financial resilience.
The strategic outlook indicates a focus on innovation and new product launches within the US market, with DRL aiming for approximately 20 launches in FY25. Overall, market sentiment remains cautiously optimistic, reflecting strong credit metrics despite recent divestments affecting the India segment.
**Investor Insight:** Given the considerable growth in revenue and effective cost management, the recommendation is to *consider purchasing shares*, as the company's competitive positioning, particularly in the US market, remains robust while the focus on innovation and expansion may bolster future profitability.